BEPADIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BEPADIN (BEPADIN).
Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
| Metabolism | Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes glucuronidation. |
| Excretion | Primarily renal excretion (70-80% unchanged) with minor biliary/fecal elimination (10-15%) |
| Half-life | 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment |
| Protein binding | 95-98% bound primarily to albumin |
| Volume of Distribution | 0.2-0.4 L/kg indicating moderate tissue distribution |
| Bioavailability | Oral: 60-75%; complete with IV administration |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes |
| Duration of Action | 4-6 hours following single dose; extended with repeated dosing |
5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, reduce dose by 50% or increase dosing interval to every other day. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use not recommended. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | Initiate at 2.5 mg once daily; titrate slowly due to increased sensitivity and risk of falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BEPADIN (BEPADIN).
| Breastfeeding | Not known if excreted in human milk. M/P ratio not established. Caution advised; consider risk-benefit. Monitor infant for excessive sedation and feeding difficulties. |
| Teratogenic Risk | Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use with caution; may cause fetal bradycardia and hypotension. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Pregnancy (second and third trimesters)","Hypersensitivity to bepadin or any component","Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min)"]
| Precautions | ["Fetal toxicity: Use in pregnancy can cause fetal harm; discontinue as soon as possible when pregnancy is detected","Hypotension in volume-depleted patients","Renal function deterioration in patients with bilateral renal artery stenosis or single kidney","Hyperkalemia, especially in renal impairment or concomitant use of potassium-sparing diuretics","Avoid use with aliskiren in patients with diabetes"] |
| Food/Dietary | No significant food interactions reported. Grapefruit juice does not affect bepotastine metabolism. Avoid excessive alcohol intake due to potential for increased sedation. |
Loading safety data…
| Maternal: heart rate, blood pressure, ECG, renal function, electrolytes, fluid balance. Fetal: heart rate monitoring (non-stress test) in third trimester; ultrasound for growth and amniotic fluid volume. |
| Fertility Effects | No controlled human studies. Animal studies show no impairment of fertility at therapeutic doses. Reversible hormonal changes may occur in women. |
| Clinical Pearls | BEPADIN (bepotastine besilate), a second-generation antihistamine, is indicated for allergic rhinitis and urticaria. It does not require hepatic metabolism, making it suitable for patients with liver impairment. Onset of action is within 1 hour. Avoid concurrent use with CNS depressants due to additive sedative effects. |
| Patient Advice | Take once daily in the morning or as directed by your physician. · Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness. · Avoid alcohol consumption as it can intensify drowsiness. · Report any severe allergic reactions, such as difficulty breathing or swelling, to your healthcare provider immediately. · Store at room temperature away from moisture and heat. |